Craig Stemmer
Nephrology · Boca Raton, FLNPI 1013900299
Payments from drug & device makers
Across 106 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$492
- Abbott$437
- Amgen$282
- Otsuka America Pharmaceutical, Inc.$235
- Novo Nordisk$163
- Aurinia Pharma U.S., Inc.$120
- plus $456 from 12 others
What the payments were for
- Food & beverage$2,185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 28 | $492 |
| Abbott | 22 | $437 |
| Amgen(2 entities) | 12 | $282 |
| Otsuka America Pharmaceutical, Inc. | 11 | $235 |
| Novo Nordisk | 8 | $163 |
| Aurinia Pharma U.S., Inc. | 1 | $120 |
| Mallinckrodt Hospital Products Inc. | 3 | $71 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| OPKO Pharmaceuticals, LLC | 3 | $58 |
| GSK | 3 | $52 |
| Medtronic | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Vifor Pharma, Inc. | 2 | $29 |
| Novartis | 1 | $23 |
| Fresenius USA Marketing, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUPKYNIS$120
How this compares
$2,185 in reported general payments places this provider in the 55th percentile of 756 nephrology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $43,563 |
| FarxigaDapagliflozin Propanediol | 17 | $20,861 |
| Rosuvastatin Calcium | 47 | $680 |
| Losartan Potassium | 44 | $492 |
| Metoprolol Succinate | 27 | $386 |
| Ezetimibe | 20 | $367 |
| Pantoprazole Sodium | 22 | $329 |
| Potassium Chloride | 15 | $259 |
| Atorvastatin Calcium | 32 | $233 |
| Pravastatin Sodium | 13 | $233 |
| Levothyroxine Sodium | 24 | $214 |
| Tamsulosin Hcl | 13 | $176 |
| Lisinopril | 22 | $162 |
| Amlodipine Besylate | 43 | $143 |
| Allopurinol | 15 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $163 | $43,56332 claims |
| AstraZenecaFarxiga | $492 | $20,86117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 756 nephrology providers in Florida.
Other nephrology in Boca Raton
- Marc RichardsBoca Raton$332K
- Jared JaffeBoca Raton$266K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.